Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 136

Sort by

Sort Order Select

Journal Articles

Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3)

Ehab Atallah, Emily Giever, Jorge Cortes, Ryan Conrardy, Lisa Rein, Arielle Baim, Idayat Akinola, James Thompson, Yan Gao, Richard Larson, Ravi Bhatia, B. Douglas Smith, Kathryn Flynn

Blood (2025) 146 (Supplement 1): 2844.

https://doi.org/10.1182/blood-2025-2844

Published: 2025

Journal Articles

DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors

Shirley Mo, Alex Ambinder, Amy DeZern, B. Douglas Smith, Ephraim Fuchs, Gabriel Ghiaur, Gabrielle Prince, Ivana Gojo, Javier Bolanos-Meade, Jonathan Webster, Lukasz Gondek, Richard Jones, Tania Jain, Theodoros Karantanos, William Dalton, Mark Levis

Blood (2025) 146 (Supplement 1): 1710.

https://doi.org/10.1182/blood-2025-1710

Published: 2025

Journal Articles

Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques

John Claiborne, Venkata Preetam Sandeep Kaduluri, Hua-Ling Tsai, Ivana Gojo, Amy DeZern, B. Douglas Smith, Tania Jain, Gabrielle Prince, Javier Bolanos-Meade, Ephraim Fuchs, Gabriel Ghiaur, Lukasz Gondek, William Dalton, Theodoros Karantanos, Ravi Varadhan, Mark Levis, Richard Jones, Jonathan Webster, Alex Ambinder

Blood (2025) 146 (Supplement 1): 44.

https://doi.org/10.1182/blood-2025-44

Published: 2025

Journal Articles

Outcomes of adolescent and young adult patients with AML treated on adult versus pediatric protocols

Ira Kraft, Venkata Preetam Sandeep Kaduluri, Kelsey Pandrangi, John Molina, Jonathan Webster, B. Douglas Smith, Alex Ambinder, Heather Symons

Blood (2025) 146 (Supplement 1): 2832.

https://doi.org/10.1182/blood-2025-2832

Published: 2025

Journal Articles

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Blood (2025) 146 (Supplement 1): 904.

https://doi.org/10.1182/blood-2025-904

Published: 2025

Journal Articles

Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms

Laura Walsh, Venkata Preetam Sandeep Kaduluri, Amy DeZern, Gabrielle Prince, Jonathan Webster, Tania Jain, Theodoros Karantanos, William Dalton, Ivana Gojo, Alex Ambinder, B. Douglas Smith, Lukasz Gondek, Mark Levis, Gabriel Ghiaur

Blood (2025) 146 (Supplement 1): 5227.

https://doi.org/10.1182/blood-2025-5227

Published: 2025

Journal Articles

CAR-seet 01: A pilot study for diagnosing CRS and icans using wearable consumer devices

Nazila Shafagati, corey baker, Nina Wagner-Johnston, B. Douglas Smith, Syed Abbas Ali, mariana salvatori, Ravi Varadhan, Philip Imus, Cole Sterling

Blood (2025) 146 (Supplement 1): 2641.

https://doi.org/10.1182/blood-2025-2641

Published: 2025

Journal Articles

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

John Preston Claiborne, Daniel Li, B. Douglas Smith, Mark J. Levis, Ivana Gojo, Amy E. DeZern, Alexander J. Ambinder, Tania Jain, Gabrielle T. Prince, Lukasz P. Gondek, Theodoros Karantanos, Gabriel Ghiaur, William Brian Dalton, Jonathan Allen Webster

Blood (2024) 144 (Supplement 1): 5904.

https://doi.org/10.1182/blood-2024-207608

Published: 2024

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

Decitabine Synergizes with Replication Checkpoint Inhibitors in TP53 -Mutated Acute Myeloid Leukemia

Clifford M. Csizmar, Antoine N. Saliba, Kevin L. Peterson, Xue Wei Meng, B. Douglas Smith, Gabriel Ghiaur, Mrinal M. Patnaik, Scott H. Kaufmann

Blood (2024) 144 (Supplement 1): 5782.

https://doi.org/10.1182/blood-2024-208583

Published: 2024

Journal Articles

Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax

B. Douglas Smith, Curtis A. Lachowiez, Alexander J. Ambinder, Gary Binder, Anne Angiolillo, Ravi Potluri, Eros Papademetriou, Thomas W. LeBlanc

Blood (2024) 144 (Supplement 1): 2855.

https://doi.org/10.1182/blood-2024-210603

Published: 2024

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study

B. Douglas Smith, Curtis A Lachowiez, Alexander Joseph Ambinder, Gary Binder, Anne Angiolillo, Assaf Vestin, Robert Paglia, Ravi Potluri, Eros Papademetriou, Thomas W LeBlanc

Blood (2023) 142 (Supplement 1): 971.

https://doi.org/10.1182/blood-2023-173033

Published: 2023

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Acute Leukemia and COVID-19: The Johns Hopkins Experience

Karin Paige Miller, Patrick A. Brown, B. Douglas Smith, Jonathan Webster, Helen Powell, Amy S. Duffield

Blood (2021) 138 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2021-153474

Published: 2021

Journal Articles

Transplant Outcomes for IDH-Mutated AML: Good Outcomes Thanks to Keeping Good Company

Alexander Joseph Ambinder, MDMPH, Matthew L Smith, Ravi Varadhan, PhD, Amy E. DeZern, MD, Mark Levis, MD PhD, Gabriel Ghiaur, MD PhD, Richard J. Jones, MD, B. Douglas Smith, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141493

Published: 2020

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-141264

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3)

DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors

Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques

Outcomes of adolescent and young adult patients with AML treated on adult versus pediatric protocols

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms

CAR-seet 01: A pilot study for diagnosing CRS and icans using wearable consumer devices

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Decitabine Synergizes with Replication Checkpoint Inhibitors in TP53 -Mutated Acute Myeloid Leukemia

Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Acute Leukemia and COVID-19: The Johns Hopkins Experience

Transplant Outcomes for IDH-Mutated AML: Good Outcomes Thanks to Keeping Good Company

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only